Literature DB >> 13475485

Radioactivity over the spleen and liver following the transfusion of chromium51-labelled erythrocytes in hemolytic anemia.

L L SCHLOESSER, D R KORST, D V CLATANOFF, R F SCHILLING.   

Abstract

Entities:  

Keywords:  ANEMIA, HEMOLYTIC/metabolism; ERYTHROCYTES/effect of radiations on; LIVER/metabolism; SPLEEN/metabolism

Mesh：

Year:  1957        PMID： 13475485      PMCID： PMC1072747          DOI： 10.1172/JCI103544

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  8 in total

1.  Uses and limitations of survival studies of erythrocytes tagged with Cr51.

Authors:  M M STRUMIA; L TAYLOR; A B SAMPLE; L S COLWELL; A DUGAN
Journal:  Blood       Date:  1955-05       Impact factor: 22.113

2.  Clinical determination of the sites of red cell sequestration in hemolytic anemias.

Authors:  J H JANDL; M S GREENBERG; R H YONEMOTO; W B CASTLE
Journal:  J Clin Invest       Date:  1956-08       Impact factor: 14.808

3.  Results of splenectomy in auto-immune haemolytic anaemia.

Authors:  G CHERTKOW; J V DACIE
Journal:  Br J Haematol       Date:  1956-07       Impact factor: 6.998

4.  Studies of the role of the spleen in the destruction of erythrocytes.

Authors:  R WEISMAN; T H HAM; C F HINZ; J W HARRIS
Journal:  Trans Assoc Am Physicians       Date:  1955

5.  Studies of red-cell volume and turnover using radiochromium; description of a new closed method of red-cell volume measurement.

Authors:  R C READ
Journal:  N Engl J Med       Date:  1954-06-17       Impact factor: 91.245

6.  The use of radioactive chromium 51 as an erythrocyte tagging agent for the determination or red cell survival in vivo.

Authors:  F G EBAUGH; C P EMERSON; J F ROSS
Journal:  J Clin Invest       Date:  1953-12       Impact factor: 14.808

7.  Hereditary spherocytosis. II. Observations on the role of the spleen.

Authors:  L E YOUNG; R F PLATZER; D M ERVIN; M J IZZO
Journal:  Blood       Date:  1951-11       Impact factor: 22.113

8.  Ferrokinetics in normal persons and in patients having various erythropoietic disorders.

Authors:  R L HUFF; P J ELMLINGER; J F GARCIA; J M ODA; M C COCKRELL; J H LAWRENCE
Journal:  J Clin Invest       Date:  1951-12       Impact factor: 14.808
  8 in total
  14 in total

1.  THE SPLEEN AND ANAEMIA.

Authors:  T A PRANKERD
Journal:  Br Med J       Date:  1963-08-31

2.  [THE LOCALIZATION OF ERYTHROCYTE DEGRADATION IN AUTOIMMUNE HEMOLYTIC ANEMIAS. STUDIES WITH CR51].

Authors:  H HEIMPEL; H SCHUBOTHE
Journal:  Blut       Date:  1964-11

3.  [THE HEMOLYTIC SYNDROME IN ACUTE AND CHRONIC HEPATITIS].

Authors:  P G FRICK; J R SCHMID
Journal:  Klin Wochenschr       Date:  1965-03-15

4.  [Problem of autoimmune hemolytic anemias].

Authors:  W WEINER
Journal:  Klin Wochenschr       Date:  1960-09-15

5.  Radioactive isotopes in medicine: a review.

Authors:  C J HAYTER
Journal:  J Clin Pathol       Date:  1960-09       Impact factor: 3.411

6.  [Hematological studies on radioactive chromium].

Authors:  W PRIBILLA; W ERNST; W ROTTGEN
Journal:  Klin Wochenschr       Date:  1959-01-01

7.  [The survival time of Cr-51 labeled erythrocytes in hematological diseases before and after splenectomy. The value of Cr-51-labeled sodium chromate in determination of indication for splenectomy and for evaluation of the effect of surgery].

Authors:  H A SCHMIDT; W KEIDERLING
Journal:  Klin Wochenschr       Date:  1960-04-01

8.  Quantitative assessment of sensing and sequestration of spherocytic erythrocytes by the human spleen.

Authors:  Innocent Safeukui; Pierre A Buffet; Guillaume Deplaine; Sylvie Perrot; Valentine Brousse; Alioune Ndour; Marie Nguyen; Odile Mercereau-Puijalon; Peter H David; Geneviève Milon; Narla Mohandas
Journal:  Blood       Date:  2012-04-17       Impact factor: 22.113

Review 9.  [Hereditary spherocytosis].

Authors:  H Esselborn; G W Löhr
Journal:  Blut       Date:  1970

10.  Red cell survival studies in hereditary spherocytosis.

Authors:  J S Wiley
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.